OBX-115 is under clinical development by Obsidian Therapeutics and currently in Phase I for Metastatic Melanoma. According to GlobalData, Phase I drugs for Metastatic Melanoma have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how OBX-115’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
OBX-115 is under development for treatment of solid tumours, cervical cancer, non-small cell lung cancer, metastatic melanoma, head and neck cancer squamous cell carcinoma. The therapy comprises of engineered tumour infiltrating lymphocytes, armoured with regulated membrane-bound IL-15. It is developed based on cytoDRiVE technology. It is administered through intravenous route.
Obsidian Therapeutics overview
Obsidian Therapeutics operates as a biotechnology company developing cell and gene immunotherapies with pharmacologic operating systems for treating cancer and other diseases. The company’s pipeline products include cytoTIL, OBX-115 – melonoma, OBX-115 – additional solid tumors, cytoTIL-X1, cytoTIL-X2, CD40L, IL12, gene editing. It discovers and develops adoptive cell therapies for the treatment of patients with cancer diseases. Obsidian’s cytoDRiVE discovery platform enables rapid optimization of tunable and functional proteins. It partners with with Bristol Myers Squibb (BMS) and Vertex Pharmaceuticals in leveraging its cytoDRiVE platform technology. Obsidian Therapeutics is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of OBX-115’s drug-specific PTSR and LoA scores, buy the report here.